DD IS Thank You Graphic_OIS-Net


1:00 – 1:15 PM

Welcome & Drug Delivery Market Overview

Presented by:
Sharon Bakalash, MD, PhD, CBA, Founder & CEO - SB Strategic Development Consultants

1:15 – 2:20 PM

Company Showcase

Eyevensys | Francine Behar-Cohen, MD, PhD - Founder & Chief Innovation Officer
EyePoint Pharmaceuticals | Nancy Lurker - President & CEO
Re-Vana Therapeutics | Michael O’Rourke - CEO
Graybug Vision | Fred Guerard - CEO
LayerBio | Kenneth Mandell, MD, PhD - CEO
PolyActiva | Russell Tait, BPharm, PhD, MBA - CEO
TALLC | Damon Smith, PhD - CEO
Kedalion Therapeutics | Mark Blumenkranz, MD, MMS - Chairman, CEO & Co-Founder
Eyenovia | Sean Ianchulev, MD, MPH - Professor of Ophthalmology – New York Eye and Ear Infirmary / Founder & CEO

2:20 – 3:00 PM

Are you a Porsche or a truck? Drug Delivery Methodologies & Strategies Panel

Jim Cunningham, Executive Director of Drug Delivery and Pharmaceutical Development - Allergan
Reza Haque, MD, PhD, Senior Vice President and Global Head of Ophthalmic Innovation Center - Santen
Joshua Horvath, PhD, Director, Device and Packaging Development - Genentech
Casey C. Kopczynski, PhD, Chief Scientific Officer & Co-Founder - Aerie Pharmaceuticals

Moderated by:
Sharon Bakalash, MD, PhD, CBA, Founder & CEO - SB Strategic Development Consultants

3:00 – 4:00 PM

Virtual Networking


Aerie Pharmaceuticals

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. In the United States, Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices and clinical development activities in Europe and Japan. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% has been approved in the EU and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% has been filed with the EMA. Aerie is also pursuing additional product candidates in ophthalmology, including a Phase 2 dry eye program, AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant, and exploring the development potential of other assets from its proprietary library of small-molecule multi-kinase inhibitors.


Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQTM (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.


Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases.

Piper Sandler

Our investment banking group has advised hundreds of clients across our core focus sectors—healthcare, energy & renewables, consumer & retail, financial services, agriculture, biorenewables & cannabis, chemicals & materials, technology, diversified industrials and business services. With a full suite of products and services, we advise our clients throughout the entire business lifecycle—from private placements and M&A advisory to providing access to the equity and debt capital markets.

Commitment to putting our clients’ interest first is the cornerstone of our guiding principles and our success is predicated upon our enduring relationships with our clients and the longevity and continuity of our team of professionals.



Learn how your company can get involved in another successful OIS meeting.


Gain valuable exposure and visibility for your company's branding.


Weekly Newsletters About The Latest In Ophthalmic Innovation.